CN102971001A - 使用生长因子再靶向内肽酶治疗癌症的方法 - Google Patents

使用生长因子再靶向内肽酶治疗癌症的方法 Download PDF

Info

Publication number
CN102971001A
CN102971001A CN2010800456673A CN201080045667A CN102971001A CN 102971001 A CN102971001 A CN 102971001A CN 2010800456673 A CN2010800456673 A CN 2010800456673A CN 201080045667 A CN201080045667 A CN 201080045667A CN 102971001 A CN102971001 A CN 102971001A
Authority
CN
China
Prior art keywords
seq
bont
cancer
peptide
aminoacid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800456673A
Other languages
English (en)
Chinese (zh)
Inventor
B·P·S·杰克伊
P·E·加里
Y·莫利纳
D·G·斯特萨克思
J·弗朗西斯
K·R·奥基
E·费尔南德斯-萨拉斯
L·E·斯图尔德
S·甘沙尼
T·J·亨特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN102971001A publication Critical patent/CN102971001A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2010800456673A 2009-08-14 2010-08-16 使用生长因子再靶向内肽酶治疗癌症的方法 Pending CN102971001A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23394709P 2009-08-14 2009-08-14
US61/233,947 2009-08-14
PCT/US2010/045659 WO2011020115A2 (en) 2009-08-14 2010-08-16 Methods of treating cancer using growth factor retargeted endopeptidases

Publications (1)

Publication Number Publication Date
CN102971001A true CN102971001A (zh) 2013-03-13

Family

ID=43478303

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800456673A Pending CN102971001A (zh) 2009-08-14 2010-08-16 使用生长因子再靶向内肽酶治疗癌症的方法

Country Status (9)

Country Link
US (2) US20110070186A1 (https=)
EP (1) EP2464366A2 (https=)
KR (1) KR20140015129A (https=)
CN (1) CN102971001A (https=)
AU (1) AU2010282274A1 (https=)
CA (1) CA2771181A1 (https=)
IL (1) IL218066A0 (https=)
IN (1) IN2012DN02046A (https=)
WO (1) WO2011020115A2 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104634982A (zh) * 2013-11-06 2015-05-20 中国科学院上海生命科学研究院 Vegf-c在制备败血症及重症细菌感染诊断试剂中的用途
CN107076749A (zh) * 2014-09-16 2017-08-18 瑞泽恩制药公司 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志
CN107847563A (zh) * 2015-03-03 2018-03-27 威尔弗雷德·杰弗里斯 用2型先天淋巴样细胞、白细胞介素33和/或干扰素诱导蛋白44调节癌症免疫
CN108070651A (zh) * 2016-11-07 2018-05-25 苏州安康盟医疗科技有限公司 一种评估crc复发风险的诊断分析/预后分析方法
WO2018141313A3 (en) * 2018-04-17 2019-02-21 Novo Nordisk A/S USE OF FGF-4 COMPOUNDS
CN113597470A (zh) * 2019-01-16 2021-11-02 益普生生物制药有限公司 分选酶标记的梭菌神经毒素
CN113621690A (zh) * 2021-07-26 2021-11-09 山西医科大学 白细胞介素32作为靶点在筛选靶向治疗食管鳞癌药物中的应用
CN114075272A (zh) * 2020-08-10 2022-02-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法
CN114295839A (zh) * 2021-08-11 2022-04-08 首都医科大学附属北京地坛医院 Hoxb7蛋白在制备用于鉴别少突胶质细胞瘤和星形细胞瘤的试剂盒中的应用
CN114907485A (zh) * 2021-02-08 2022-08-16 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN115991762A (zh) * 2022-08-24 2023-04-21 温州医科大学 重组人源fgf4蛋白及其在皮肤创面修复中的应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US11078248B2 (en) 2010-03-19 2021-08-03 Lifenet Health BMP peptides and methods of use
US20130261062A1 (en) 2010-10-14 2013-10-03 Allergan, Inc. Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
WO2012112422A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
WO2012135304A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Vagal nerve-based disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
AR086245A1 (es) * 2011-05-02 2013-11-27 Baxter Int Peptidos de union a fibrina en base a fgf
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
US20150064163A1 (en) 2011-09-02 2015-03-05 Lifenet Health BMP Peptides & Methods of Use
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
WO2014100019A1 (en) 2012-12-18 2014-06-26 Allergan, Inc. Prophylactic treatment of herpes recurrence
KR102277147B1 (ko) * 2017-12-13 2021-07-13 건국대학교 산학협력단 섬유아 성장인자 유래 펩타이드의 골 또는 연골 분화 촉진 용도
GB202307380D0 (en) * 2023-05-17 2023-06-28 Ucl Business Ltd Therapeutic molecules

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
AU2005311086B2 (en) 2004-12-01 2012-03-29 Allergan, Inc. Fusion proteins
AU2005311098B2 (en) 2004-12-01 2011-08-11 Allergan, Inc. Non-cytotoxic protein conjugates
AU2006227816B2 (en) 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
AU2007272515B2 (en) * 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104634982A (zh) * 2013-11-06 2015-05-20 中国科学院上海生命科学研究院 Vegf-c在制备败血症及重症细菌感染诊断试剂中的用途
CN107076749A (zh) * 2014-09-16 2017-08-18 瑞泽恩制药公司 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志
CN107076749B (zh) * 2014-09-16 2020-12-29 瑞泽恩制药公司 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志
US11213571B2 (en) 2015-03-03 2022-01-04 Cava Healthcare Inc. Modulation of cancer immunity with type 2 innate lymphoid cells, interleukin 33, and/or interferon induced protein 44
CN107847563A (zh) * 2015-03-03 2018-03-27 威尔弗雷德·杰弗里斯 用2型先天淋巴样细胞、白细胞介素33和/或干扰素诱导蛋白44调节癌症免疫
CN108070651A (zh) * 2016-11-07 2018-05-25 苏州安康盟医疗科技有限公司 一种评估crc复发风险的诊断分析/预后分析方法
WO2018141313A3 (en) * 2018-04-17 2019-02-21 Novo Nordisk A/S USE OF FGF-4 COMPOUNDS
CN113597470A (zh) * 2019-01-16 2021-11-02 益普生生物制药有限公司 分选酶标记的梭菌神经毒素
CN114075272A (zh) * 2020-08-10 2022-02-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法
CN114075272B (zh) * 2020-08-10 2023-09-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法
CN114907485A (zh) * 2021-02-08 2022-08-16 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN113621690A (zh) * 2021-07-26 2021-11-09 山西医科大学 白细胞介素32作为靶点在筛选靶向治疗食管鳞癌药物中的应用
CN113621690B (zh) * 2021-07-26 2023-08-22 山西医科大学 白细胞介素32作为靶点在筛选靶向治疗食管鳞癌药物中的应用
CN114295839A (zh) * 2021-08-11 2022-04-08 首都医科大学附属北京地坛医院 Hoxb7蛋白在制备用于鉴别少突胶质细胞瘤和星形细胞瘤的试剂盒中的应用
CN114295839B (zh) * 2021-08-11 2024-06-07 首都医科大学附属北京地坛医院 Hoxb7蛋白在制备用于鉴别少突胶质细胞瘤和星形细胞瘤的试剂盒中的应用
CN115991762A (zh) * 2022-08-24 2023-04-21 温州医科大学 重组人源fgf4蛋白及其在皮肤创面修复中的应用
CN115991762B (zh) * 2022-08-24 2025-08-29 温州医科大学 重组人源fgf4蛋白及其在皮肤创面修复中的应用

Also Published As

Publication number Publication date
WO2011020115A2 (en) 2011-02-17
IL218066A0 (en) 2012-04-30
CA2771181A1 (en) 2011-02-17
US20110070186A1 (en) 2011-03-24
IN2012DN02046A (https=) 2015-08-21
AU2010282274A1 (en) 2012-03-15
KR20140015129A (ko) 2014-02-06
EP2464366A2 (en) 2012-06-20
US20130195838A1 (en) 2013-08-01
WO2011020115A3 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
CN102971001A (zh) 使用生长因子再靶向内肽酶治疗癌症的方法
CN102573876A (zh) 使用甘丙肽再靶向内肽酶治疗癌症的方法
US20130224178A1 (en) Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopepidases
US20110070215A1 (en) Methods of treating cancer using neurotrophin retargeted endopeptidases
KR20120061878A (ko) 타키키닌 재표적화된 엔도펩티다아제를 사용하여 암을 치료하는 방법
CN102574900A (zh) 使用阿片样物质再靶向内肽酶治疗癌症的方法
US20120207733A1 (en) Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
WO2012112434A1 (en) Inhibiting aberrant blood vessel formation using retargeted endopeptidases
US20120207704A1 (en) Inhibiting Aberrant Blood Vessel Formation Using Growth Factor Retargeted Endopeptidases
US20120207742A1 (en) Treatments Using PSMA Ligand Endopeptidases
US20120207734A1 (en) Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
WO2012112432A1 (en) Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130313